Cognition Therapeutics – Could This Company's Technology Make Debilitating Neural Diseases Like Dementia A Thing Of The Past?

Cognition Therapeutics, Inc. (NASDAQ: CGTX) is a clinical stage neuroscience company developing drugs that help restore normal cellular damage responses in neurodegenerative and neuro-ophthalmic disorders.

The company’s technology “selectively modulates” a central cellular damage response pathway, allowing the body to heal itself. It believes its technology could be a huge leap forward in combating these debilitating diseases.

The company has recently added a new CFO in John Doyle as well as announced positive topline results from a key study.

Learn more here:

Featured photo by Robina Weermeijer on Unsplash.

This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.